Researchers examined 266 patients from the University of Pittsburgh Medical Center whose tumors were surgically removed. Sixty-seven percent received post-surgery chemotherapy and/or radiotherapy. Median overall survival was five and a half years.
Around 28 percent of patients in the study had a mutated PIK3CA gene, which is the most commonly altered oncogene for head and neck cancers.
The research team found that regular use of non-steroidal anti-inflammatory drugs for six months provided significantly improved survival rates among head and neck cancer patients who had the mutated PIK3CA gene, as compared to patients with the mutation who did not use NSAIDs; the medications increased overall five-year survival rates from 25 percent to 78 percent.
However, patients without the gene mutation did not experience improved survival by taking NSAIDs.
More articles on healthcare quality:
How AI can help physicians communicate with patients, improve care
Patient safety advocates back laws to improve maternal hospital care
Mount Carmel CEO: We should have acted faster with physician accused of fatal prescriptions
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.